Compare Ishares Msci Brazil ETF (EWZ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Novavax Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.53 (market cap $11.30B), while Novavax Inc trades at $12.2 (market cap $1.82B). The key difference: Ishares Msci Brazil ETF is far larger — about 6.2× Novavax Inc's market cap, and Ishares Msci Brazil ETF is more actively traded (44,036,597 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Novavax Inc for 59 Days on average.
| EWZ | NVAX | |
|---|---|---|
Market Cap | $11.30B | $1.82B |
Volume | 44,036,597 | 6,198,505 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $12.56 |
52-Week Low | $28.79 | $6.22 |
Typical Hold Time | 50 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $43.14, up 1.82% with strong bullish momentum from moving averages but overbought RSI signals. The ETF shows unusual options activity and institutional interest, driven by Brazil's upcoming election and commodity exposure. Recent news highlights Wall Street positioning for potential policy shifts under different election outcomes, with the fund serving as a diversification tool from U.S. tech concentration.
Outlook remains election-dependent with asymmetric upside potential through call options. Risks include political volatility, U.S.-Brazil trade tensions, and currency fluctuations. The technical setup suggests near-term consolidation near pivot points while fundamentals rely on Brazil's economic policies and commodity performance.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
